Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum tolerated dose of the
combination taxotere, cisplatin, 5-fluorouracil and leucovorin. We will also preliminarily
assess whether the combination is effective in treating squamous cell carcinoma of the head
and neck.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Sanofi